# Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

> **NCT00775606** · PHASE4 · TERMINATED · sponsor: **Rush University Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Acquired Immune Deficiency Syndrome

## Interventions

- **DRUG:** Lopinavir 400 mg/ritonavir 100 mg
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00775606
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
- **Last updated:** 2023-05-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00775606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00775606, "Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00775606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*